title: [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
abstract: BACKGROUND
  Patients treated with haemodialysis have a high prevalence of co-morbidity that induces a elevate mortality risk. On the other hand, these patients have anaemia whose treatment is based in erythropoiesis stimulating agents. To date there are not enough studies to determine if co-morbidity alters erythropoietin response and the relationship between co-morbidity, response to treatment of anaemia and resistance to erythropoiesis-stimulating agents.
  
  
  OBJECTIVE
  We have the following objectives: i) to study the prevalence of associated diseases in patients treated with haemodialysis in our Hospital Unit and to evaluate the co-morbidity Charlson Index, ii) to know the degree of anaemia control, dose and response to erythropoiesis-stimulating agents, and iii) to determine the relationship with co-morbidity and anaemia treatment.
  
  
  METHODS
  We designed a retrospective study in stable haemodialysis treated patients. We calculated the Charlson co-morbidity index adjusted to age and we analysed levels of haemoglobin in the 6 months before study, dose of erythropoiesis-stimulating agents and its resistance index defined as doses of erythropoiesis-stimulating agents/weight (kg)/week/haemoglobin (g/dL). The different variables included in Charlson index were considered as independent variables and the index to repose to erythropoiesis-stimulating agents as a dependent variable, using bivariant and multivariate statistical analysis.
  
  
  RESULTS
  We included 58 patients (31 males and 27 females), median age of 69.5 years (range 24-88), mean haemodialysis 83.7 months. Mean Charlson index was 7.4 +/- 2.8 (range 2-13). Comorbidity-age Charlson index was 2 in 3.4% of patients; 10.3% had 3 or 4 points; 43.2% between 5 and 7 and 43,1% 8 or more. Mean haemoglobin levels was 11,7+/-1,2 g/dL. Mean erythropoiesis-stimulating agents dose was 163.7+/-114.5 IU/kg/week and resistance index 14.1+/-9.7. Most of patients (57%) had a IRE value higher than 10. Fourteen patients (24%) had haemoglobin less than 11 g/dL, and 3 of them (5.1%) received erythropoiesis-stimulating agents more than 300 IU/kg/week. Nine subjects (15.5%) was treated with high dose of erythropoiesis-stimulating agents (>300 IU/kg/week): 3 of them had Hb>or=11 g/dL and 6 had Hb<11 g/dL. We did not found that the intensity of Charlson index is related with the degree of anaemia control or response to erythropoiesis-stimulating agents.
  
  
  CONCLUSIONS
  Although the co-morbidity index is high and the response to erythropoiesis-stimulating agents is inadequate. In our study there is not relationship between these conditions.
authors.affiliation: Sección de Nefrología, Hospital General Ciudad Real. sara.anaya@senefro.org
authors.forename: S
authors.initials: S
authors.lastname: Anaya
authors.forename: F
authors.initials: F
authors.lastname: Rivera
authors.forename: M D
authors.initials: MD
authors.lastname: Sánchez de la Nieta
authors.forename: A
authors.initials: A
authors.lastname: Carreño
authors.forename: C
authors.initials: C
authors.lastname: Vozmediano
authors.forename: M P
authors.initials: MP
authors.lastname: Alcaide
authors.forename: M
authors.initials: M
authors.lastname: Arambarri
authors.forename: J
authors.initials: J
authors.lastname: Nieto
authors.forename: G
authors.initials: G
authors.lastname: Caparrós
authors.forename: I
authors.initials: I
authors.lastname: Ferreras
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000150:complications* / Q000188:drug therapy*; D016022:Case-Control Studies; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012189:Retrospective Studies
chemical_list: D006397:Hematinics